Modality
Vaccine
MOA
Anti-Aβ
Target
GLP-1R
Pathway
Angiogenesis
HNSCCOvarian Ca
Development Pipeline
Preclinical
~Jul 2020
→ ~Oct 2021
Phase 1
~Jan 2022
→ ~Apr 2023
Phase 2
Jul 2023
→ Dec 2029
Phase 2Current
NCT07931722
2,632 pts·Ovarian Ca
2023-07→2029-04·Completed
NCT04849549
1,728 pts·Ovarian Ca
2023-12→2029-12·Recruiting
4,360 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-04-253.1y awayPh2 Data· Ovarian Ca
2029-12-093.7y awayPh2 Data· Ovarian Ca
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Complet…
P2
Recruit…
Catalysts
Ph2 Data
2029-04-25 · 3.1y away
Ovarian Ca
Ph2 Data
2029-12-09 · 3.7y away
Ovarian Ca
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07931722 | Phase 2 | Ovarian Ca | Completed | 2632 | EDSS |
| NCT04849549 | Phase 2 | Ovarian Ca | Recruiting | 1728 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Mavuglumide | Bayer | Approved | GLP-1R |